Ivan Hyep Sells 6,415 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Key Points

• CFO Ivan Hyep sold 6,415 shares of Bicara Therapeutics at an average price of $18.23, totaling approximately $116,945, which decreased his ownership by 4.23%.
• Bicara Therapeutics' stock has a recent trading price of $17.78, lower than its one-year high of $28.09 and has a market capitalization of $971 million.
• Analysts have varied ratings on Bicara Therapeutics, with a consensus of "Moderate Buy" and an average price target of $31.86.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 6,415 shares of the business's stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of $18.23, for a total transaction of $116,945.45. Following the completion of the transaction, the chief financial officer owned 145,355 shares of the company's stock, valued at approximately $2,649,821.65. The trade was a 4.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ivan Hyep also recently made the following trade(s):

• On Tuesday, October 7th, Ivan Hyep sold 18,244 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.22, for a total value of $332,405.68.
• On Wednesday, October 8th, Ivan Hyep sold 5,627 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.21, for a total value of $102,467.67.
• On Monday, October 6th, Ivan Hyep sold 6,514 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.17, for a total value of $118,359.38.

Bicara Therapeutics Price Performance

Shares of Bicara Therapeutics stock traded down $0.48 during trading on Friday, hitting $17.78. 386,878 shares of the company's stock traded hands, compared to its average volume of 577,732. Bicara Therapeutics Inc. has a 1 year low of $7.80 and a 1 year high of $28.09. The stock has a market capitalization of $971.00 million and a P/E ratio of -5.61. The business has a 50-day simple moving average of $12.51 and a 200-day simple moving average of $11.87.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.04. On average, equities analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Weiss Ratings restated a "sell (e+)" rating on shares of Bicara Therapeutics in a research report on Saturday, September 27th. HC Wainwright dropped their price target on Bicara Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a research note on Friday, August 22nd. Piper Sandler began coverage on Bicara Therapeutics in a report on Monday, August 18th. They issued an "overweight" rating and a $36.00 price objective for the company. Finally, Wedbush reiterated an "outperform" rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $31.86.

Institutional Investors Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System bought a new position in Bicara Therapeutics in the 4th quarter worth $25,000. CWM LLC bought a new position in shares of Bicara Therapeutics in the first quarter worth about $29,000. Legal & General Group Plc raised its stake in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock worth $29,000 after buying an additional 1,233 shares during the period. Ameritas Investment Partners Inc. lifted its position in shares of Bicara Therapeutics by 73.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company's stock valued at $32,000 after buying an additional 1,474 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock valued at $44,000 after acquiring an additional 3,866 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.